<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00561639</url>
  </required_header>
  <id_info>
    <org_study_id>2007-A01053-50</org_study_id>
    <nct_id>NCT00561639</nct_id>
  </id_info>
  <brief_title>Benefit of SeptiFast Multiplex PCR in the Etiologic Diagnosis and Therapeutic Approach for Onco-hematology Patients Presenting Sepsis</brief_title>
  <acronym>SEPTIFAST</acronym>
  <official_title>Benefit of Septifast Multiplex PCR in the Etiologic Diagnosis and Therapeutic Approach for Onco-hematology Patients Presenting Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A SpetiFast multiplex PCR kit has recently been placed on the market witch can evidence the&#xD;
      DNA of 90% of micro-organisms (bacteria and fungus) implicated in sepsis. However, the&#xD;
      clinical impact of being able to detect the DNA of these various agents is unknown. We&#xD;
      propose to assess the benefit to patient care of the SeptiFast multiples PCR by answering&#xD;
      three questions : 1/in patients with septic immunosuppression, does this kit evidence&#xD;
      etiologic agents not revealed by classical methods? 2/Does the use of PCR results permit&#xD;
      different diagnostic hypotheses to be considered? 3/Does having the SeptiFast results entail&#xD;
      changes to the therapeutic plan?&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has double purpose :&#xD;
&#xD;
        1. To compare the results obtained from the SeptiFast system with the results from&#xD;
           classical microbiological sampling, in particular hemoculture, for immunosuppressed&#xD;
           patients presenting sepsis.&#xD;
&#xD;
        2. To perform a blind assessment of the benefit of septiFast care of these patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Actual">76</enrollment>
  <condition>Hematologic Diseases</condition>
  <condition>Sepsis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum tube will routinely be kept in the serum bank for subsequent analysis&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with onco-hematologic or cancerous pathology, or hematologic disease with&#xD;
        chemotherapy and/or radiotherapy and/or some other immunosuppressant treatment in progress&#xD;
        presenting an infection requiring hospitalisation and meeting the following criteria :&#xD;
        Sepsis and with or without organ dysfunction&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All patients with onco-hematologic or cancerous pathology, or hematologic disease with&#xD;
        chemotherapy and/or radiotherapy and/or some other immunosuppressant treatment in progress&#xD;
        presenting an infection requiring hospitalisation and meeting the following criteria:&#xD;
&#xD;
          -  Sepsis (at least one of the following signs):&#xD;
&#xD;
               -  Fever &gt; 38.2°C or hypothermia &lt; 36°C&#xD;
&#xD;
               -  FO120 min&#xD;
&#xD;
               -  PA&lt;120 mmHg (or 50 mmHg reduction in base numbers)&#xD;
&#xD;
               -  Respiratory F &gt; 30/min&#xD;
&#xD;
               -  Confusion&#xD;
&#xD;
               -  Hyperleucocytosis (&gt;12 G/l) or leucopenia (&lt;4 G/l)&#xD;
&#xD;
               -  C-Reactive protein &gt; 40&#xD;
&#xD;
          -  With or without organ dysfunction as defined by :&#xD;
&#xD;
               -  Hypoxia (PaO2/FiO2&lt;300mmHg)&#xD;
&#xD;
               -  Oliguria (urine deficiency&lt;0.5 ml/kg/h in probed patient)&#xD;
&#xD;
               -  Creatinine &gt; 200umol/l&#xD;
&#xD;
               -  INR&gt;1.5 or TCA&gt;2 X control in the absence of anticoagulant treatment&#xD;
&#xD;
               -  Platelets &lt; 100 G/l&#xD;
&#xD;
               -  Bilirubin &gt; 35 umol/l&#xD;
&#xD;
               -  Lactatemia &gt; 2 mmol/l&#xD;
&#xD;
               -  Arterial hypotension (PAS&lt;90mmHg, or PAM&lt;70mmHg or reduction of more than 40 mmHG&#xD;
                  if known hypertension)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minor patient&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  A patient cannot be included again within 15 days of his/her preceding inclusion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>TIMSIT Jean-François, PU/PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>November 20, 2007</study_first_submitted>
  <study_first_submitted_qc>November 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2007</study_first_posted>
  <last_update_submitted>July 8, 2010</last_update_submitted>
  <last_update_submitted_qc>July 8, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2010</last_update_posted>
  <responsible_party>
    <name_title>TIMSIT</name_title>
    <organization>University Hospital, Grenoble</organization>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>immunosuppressed</keyword>
  <keyword>multiplex PCR</keyword>
  <keyword>diagnosis</keyword>
  <keyword>therapeutic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

